Organ‐on‐chip for advancing CAR therapy
Abstract Despite great strides of progress, at least 60% of the responding patients relapse to CAR therapy across the blood malignancies. Off‐tumor toxicity apart from functional deficits, cytopenia and infection are the major unfavourable effect of CAR therapy. Models, which faithfully recapitulate...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wiley
2025-01-01
|
| シリーズ: | Clinical & Translational Immunology |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1002/cti2.70024 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|